-
The Future Of Nano Technology
Categories
- Ai
- Alan Watts
- Anatomy
- Andropause
- Anti-Aging Medicine
- Arthritis
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ataxia
- Autism
- Biochemistry
- BioEngineering
- Biotechnology
- Bitcoin
- Chemistry
- Cryonics
- Cryptocurrency
- David Sinclair
- Dementia
- Diet Science
- Diseases
- Eczema
- Elon Musk
- Futurism
- Gene Medicine
- Gene Therapy
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Healthy Lifestyle
- Healthy Living
- HGH Physicians
- Hormone Optimization
- Hormone Replacement Therapy
- Hormone Replacement Treatment
- Human Genetic Engineering
- Human Immortality
- Human Longevity
- Human Reproduction
- Hypogonadism
- Hypopituitarism
- Hypothyroidism
- Immortality
- Immortality Medicine
- Inflammation
- Injectable Growth Hormone
- Integrative Medicine
- Life Skills
- Longevity
- Longevity Medicine
- Low T
- Machine Learning
- Mars Colony
- Medical School
- Menopause
- multiple-sclerosis
- Nano Medicine
- Nanomedicine
- Nanotechnology
- Neurology
- Parkinson's disease
- Pharmacogenomics
- Protein Folding
- Psoriasis
- Quantum Computing
- Regenerative Medicine
- Resveratrol
- Sermorelin Physicians
- Singularity
- Spacex
- Stem Cell Therapy
- Stem Cells
- Stemcell Therapy
- Testosterone
- Testosterone Physicians
- Transhuman
- Transhumanism
- Transhumanist
- Uncategorized
- Veganism
- Vegetarianism
- Vitamin Research
- Wellness
-
Recent Posts
- Polyplus Launches Innovative Plasmid for AAV Vector Production, Strengthening Its Position in Biologic and Cell … – BSA bureau
- Orchard Sets $4.25M US Price for Gene Therapy Lenmeldy on Heels of Approval – BioSpace
- Stem Cell Editing Repairs Severe Immunodeficiency – The Scientist
- Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in … – GlobeNewswire
- New Gene Therapy for Rare MDL to Cost $4.25 Million – Managed Healthcare Executive
Archives
Popular
Search Immortality Topics: |
Category Archives: Global News Feed
Clene to Host VISIONARY-MS Results Call and Webcast on August 15
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15.
Read this article:
Clene to Host VISIONARY-MS Results Call and Webcast on August 15
Posted in Global News Feed
Comments Off on Clene to Host VISIONARY-MS Results Call and Webcast on August 15
Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
REDWOOD CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, today announced second quarter 2022 financial results and provided a corporate update.
View original post here:
Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Posted in Global News Feed
Comments Off on Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 -
See more here:
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
Posted in Global News Feed
Comments Off on Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced financial results and operational highlights for the quarter ended June 30, 2022. In addition, the Company provided an overview of recent corporate developments.
Read this article:
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Posted in Global News Feed
Comments Off on IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MIAMI, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the granting of inducement awards to five new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was made as a material inducement to the five employees’ entry into employment with the Company.
See the rest here:
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Posted in Global News Feed
Comments Off on Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022
Read the original here:
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
Posted in Global News Feed
Comments Off on Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders